What is the duration of action of Vyvanse (lisdexamfetamine) when taken once daily in the morning?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Action of Vyvanse (Lisdexamfetamine)

Vyvanse provides approximately 13-14 hours of therapeutic effect when taken once daily in the morning, making it the longest-acting ADHD stimulant medication currently available. 1, 2

Pharmacokinetic Profile and Duration

  • Lisdexamfetamine reaches peak plasma concentrations approximately 3 hours after oral administration, with d-amphetamine (the active metabolite) achieving mean peak levels around 3.0 hours post-dose at steady state. 3

  • The therapeutic effect extends through 14 hours post-dose in adults, as demonstrated in controlled trials measuring ADHD symptom control late into the day. 1

  • In pediatric patients (ages 6-12), efficacy is maintained throughout the entire school day and into early evening (approximately 6 PM), based on parent ratings conducted in morning, afternoon, and early evening timepoints. 4, 5

  • The prodrug mechanism provides a duration of approximately 12 hours according to multiple sources, though clinical trials demonstrate effects extending beyond this timeframe. 2, 6

Comparison to Other Stimulants

  • Vyvanse's 13-14 hour duration significantly exceeds other long-acting stimulants: extended-release mixed amphetamine salts (Adderall XR) provide only 8-9 hours, OROS-methylphenidate (Concerta) provides 12 hours, and immediate-release methylphenidate provides only 4-6 hours. 7

  • The extended duration eliminates the need for afternoon dosing in most patients, addressing compliance issues associated with in-school medication administration. 7

Clinical Implications for Dosing Schedule

  • Administer Vyvanse once daily in the morning to maximize daytime coverage while minimizing insomnia risk. 8, 9

  • The single daily dose covers the full school/work day plus evening activities (homework, social interactions) without requiring supplemental afternoon stimulant doses in most cases. 5

  • For patients requiring extended evening coverage beyond 14 hours or experiencing inadequate late-day symptom control, consider adding a short-acting stimulant (e.g., immediate-release dextroamphetamine 5-10 mg) in early-to-mid afternoon, but schedule no later than 2-3 PM to avoid insomnia. 9, 10

Pharmacokinetic Details

  • Steady-state d-amphetamine concentrations are reached by day 5 of daily dosing, with 95% of d-amphetamine eliminated within 48 hours following the final dose. 3

  • The prodrug itself (lisdexamfetamine) is completely eliminated approximately 6 hours post-dose, while the active d-amphetamine metabolite persists much longer to provide the extended therapeutic effect. 3

  • The rate-limited enzymatic conversion in red blood cells creates a gradual, sustained release of active d-amphetamine, explaining the extended duration despite the prodrug's rapid elimination. 2, 6

Common Pitfall to Avoid

  • Do not assume inadequate total daily dosing when patients report late-afternoon symptom return—Vyvanse's 13-14 hour duration should cover most patients' needs, so breakthrough symptoms may indicate suboptimal morning dose rather than true wearing-off, requiring dose titration upward (in 10-20 mg increments weekly to maximum 70 mg) before adding afternoon supplementation. 9

References

Guideline

Methylphenidate Extended-Release Formulations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Optimizing Vyvanse Dosing for ADHD Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Safe Combination of Vyvanse and Dexedrine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.